Leading EU-GMP pharmaceutical and biotech company SOMAÍ Pharmaceuticals (“SOMAÍ”), specializing in cannabinoid pharmaceuticals, recently announced a partnership with prominent U.S. multi-state consumer packaged goods (CPG) company AIRO BRANDS, Inc. (“Airo”), known for its proprietary cannabis products.
Details of the collaboration
As a result of this strategic partnership, SOMAÍ is granted the sole authority to produce and market Airo’s highly acclaimed medical goods in Australia, Germany, Poland, and Switzerland. In the second quarter of 2024, European and Australian consumers will be able to purchase Airo’s well-known products thanks to the cooperation, which will capitalize on SOMAÍ’s experience producing inhalation oils to the highest standards of safety and quality.
In the US, Airo has made a name for itself as a top cannabis brand. It is present in Puerto Rico as well as 23 states. The company is well known for its high-end vaporizer innovations. Here, we may distinguish between its various AiroPod oil formulations, such as Artisan, Strain, Live Flower, Live Resin, and Live Rosin, in addition to AiroPro, AiroSport, and AiroX. Airo has added ORIA to their lineup of vape products. Its collection of cannabis-infused gummies serves to further establish the company’s standing as a trailblazer in the sector.
Remarks regarding the development of Airo and SOMAÍ
Airo’s CEO, Richard Yost, said:
A key accomplishment for Airo has been taking our brand global, and it was crucial to find a partner who shared our commitment to excellence and customer care. We were impressed by SOMAÍ’s staff caliber in addition to its cutting edge facility in Portugal. It’s the ideal pairing.”
The CEO and founder of SOMAÍ Pharmaceuticals is Michael Sassano. He emphasized how crucial this collaboration is to getting Airo’s products into other markets.
“Airo is leading the way in worldwide expansion as top American companies focus on expanding into Europe. Our collaboration guarantees that SOMAÍ’s dedication to EU-GMP quality standards will allow Airo’s product offers to be accessed by consumers globally. We are pleased to provide Airo’s best-in-class vaporizers to customers in Europe and beyond as the world market continues to change.”
With the European and Australian markets embracing the burgeoning cannabis industry, SOMAÍ Pharmaceuticals’ collaboration with Airo Brands represents a significant opportunity to introduce innovative and high-quality cannabis products to a broader audience. Year 2023 was very successful for SOMAÍ especially, as Michael Sassano described in our last interview. Both companies share a commitment to excellence and consumer satisfaction. Thus, this partnership is poised to drive growth and success in the rapidly evolving global cannabis market.